Engineering Vessels as Good as New?

Engineering Vessels as Good as New?
复制标题

DOI:
10.1016/j.jacbts.2017.11.008
复制
发表时间:
2018-03
期刊:
JACC. Basic to translational science
影响因子:
--
通讯作者:
D Levit R
D Levit R
中科院分区:
其他
文献类型:
--
作者:
D Levit R

文献摘要

参考文献

被引文献

相似文献

血管将必要的营养物质输送到末端器官,当它们患病时,它们必须被替换或绕过。传统上使用塑料和合成材料,但容易发生血栓、狭窄和通畅率低。最近发表在《科学转化医学》上的一份报告描述了一种脱细胞基质,这种基质是从商业来源的成纤维细胞体外培养出来的,可以用作血管移植。成纤维细胞在纤维蛋白支架上生长数周,形成一层胶原层。在脱细胞和动静脉瘘移植后,这组患者显示移植物保持通畅达数周。移植时移植物细胞材料的缺乏降低了免疫排斥反应的风险。成纤维细胞铺设的基质可以作为移植后受体细胞定植的支架,也为动脉血流提供结构性支持。其他脱细胞基质的组织工程移植物最近也在临床试验中进行了测试。对于这些策略,细胞类型、支架材料和培养条件不仅决定了最终产品的类型和质量,而且还允许进行标准化和质量控制,以便广泛应用于临床。这些现成的脱细胞产品可能是新一代心血管疾病患者治疗方法中的第一个。
Blood vessels convey essential nutrients to end organs, and when diseased, they must be replaced or bypassed. Traditionally plastic and synthetic materials have been used but are susceptible to thrombosis, stenosis, and poor patency rates. A recent report in Science Translational Medicine describes a decellularized matrix grown in vitro from commercially sourced fibroblasts that can be used as a vascular graft. Fibroblasts are grown for several weeks on a fibrin scaffold, laying down a collagen layer. After decellularization and transplantation as an arteriovenous fistula, this group showed that grafts remained patent for several weeks. The lack of cellular material in this graft at the time of transplantation reduced the risk of immune rejection. The matrix laid down by the fibroblasts can serve as a scaffold for recipient cells to colonize after implantation, but also provides structural support for arterial blood flow. Other tissue-engineered grafts of decellularized matrices have recently been tested in clinical trial. For these strategies, the cell type, scaffold material, and culture conditions are key components that dictate not only the type and quality of the end product, but also allow standardization and quality control necessary for widespread translation into clinical use. These off-the-shelf decellularized products may be the first in a new generation of therapies for patients with cardiovascular disease.
DOI: 10.1016/j.jtcvs.2009.09.057
发表时间: 2010-02-01
影响因子: 6
作者:
Hibino, Narutoshi;McGillicuddy, Edward;Shinoka, Toshiharu
通讯作者: Shinoka, Toshiharu
DOI: 10.1126/scitranslmed.3005503
发表时间: 2013-02-20
影响因子: 17.1
作者:
Seif-Naraghi SB;Singelyn JM;Salvatore MA;Osborn KG;Wang JJ;Sampat U;Kwan OL;Strachan GM;Wong J;Schup-Magoffin PJ;Braden RL;Bartels K;DeQuach JA;Preul M;Kinsey AM;DeMaria AN;Dib N;Christman KL
通讯作者: Christman KL
DOI: 10.1126/scitranslmed.3001426
发表时间: 2011-02-02
影响因子: 17.1
作者:
Dahl, Shannon L. M.;Kypson, Alan P.;Niklason, Laura E.
通讯作者: Niklason, Laura E.
DOI: 10.1126/scitranslmed.aan4209
发表时间: 2017-11-01
影响因子: 17.1
作者:
Syedain, Zeeshan H.;Graham, Melanie L.;Tranquillo, Robert T.
通讯作者: Tranquillo, Robert T.
DOI: 10.1186/1471-2369-14-79
发表时间: 2013-04-04
期刊: BMC nephrology
影响因子: 2.3
作者:
Ocak G;Rotmans JI;Vossen CY;Rosendaal FR;Krediet RT;Boeschoten EW;Dekker FW;Verduijn M
通讯作者: Verduijn M